Dr. Chen-Walden has specialized in regulatory affairs in the pharmaceutical industry in the US and Europe. She has thirty years of regulatory experience in EMEA and in individual European countries. Since 2004, She has consulted for the European Clinical and Regulatory Consultancy in medical monitoring, quality assurance, and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases, and medical devices. From 2000 to 2003, Dr. Chen-Walden was Director of International Regulatory Affairs, Covalent Group Ltd. From 1997 to 2000, she was Medical, Drug Safety, and Regulatory Director at CRC, a clinical contract research organization in France. Dr. Chen-Walden received her MD degree from the University of Tel Aviv, Israel. She has practiced medicine in Germany and France.
Anders N. Utter
Mr. Utter has more than 25 years of finance, accounting and management experience in medical devices, consulting and manufacturing industries in capacities as CFO, Controller and Managing Director. He had progressively increased management experience in the European Nolato Group and later on in the Amplex Group. Mr. Utter has had a broad business exposure with IFRS and GAAP reporting as well as with SOX compliance. He has also worked with M&A evaluations, financing and integration as well as more hands-on manufacturing cost accounting and reporting. He is currently in charge of the finance control at one of General Cable’s entities. Mr. Utter is and has been serving as a director on boards in both profit as well as non-profit organizations. Mr. Utter holds an MBA from Babson College and a BA from Uppsala University in Sweden.
Alan M. Hoberman
Alan M. Hoberman, PhD is president and CEO of Argus International, Inc., overseeing a staff of scientists and other professionals who provide consulting services for industry, government agencies, law firms, and other organizations, both in the U.S. and internationally. Between 1991 and 2013 he held a series of positions of increasing responsibility at Charles River Laboratories Preclinical Services (formerly Argus Research Laboratories, Inc.), most recently as Executive Director of Site Operations and Toxicology. He currently works with that organization to design, supervise, and evaluate reproductive and developmental toxicity, neurotoxicity, inhalation, and photobiology studies. Dr. Hoberman holds a PhD in toxicology from Pacific Western University, an MS in interdisciplinary toxicology from the University of Arkansas, and a BS in biology from Drexel University.
Dale H. Conaway
We are proud to have Dr.Dale H. Conaway as a board member at Bioxytran Inc. From 1998 to 2001, Dr. Conaway served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture. From 1994 to 1998, he was Regulatory Affairs Manager for the Michigan Department of Public Health Vaccine Production Division. From May 2001 to February 2009, Dr. Conaway was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. Dr. Conaway received a DVM degree from Tuskegee Institute and an MS degree in pathology from the College of veterinary medicine at Michigan State University.